Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

51 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Low MAD2 expression levels associate with reduced progression-free survival in patients with high-grade serous epithelial ovarian cancer.
Furlong F, Fitzpatrick P, O'Toole S, Phelan S, McGrogan B, Maguire A, O'Grady A, Gallagher M, Prencipe M, McGoldrick A, McGettigan P, Brennan D, Sheils O, Martin C, W Kay E, O'Leary J, McCann A. Furlong F, et al. J Pathol. 2012 Apr;226(5):746-55. doi: 10.1002/path.3035. Epub 2012 Jan 17. J Pathol. 2012. PMID: 22069160 Free PMC article.
Overexpression of the microRNA miR-433 promotes resistance to paclitaxel through the induction of cellular senescence in ovarian cancer cells.
Weiner-Gorzel K, Dempsey E, Milewska M, McGoldrick A, Toh V, Walsh A, Lindsay S, Gubbins L, Cannon A, Sharpe D, O'Sullivan J, Murphy M, Madden SF, Kell M, McCann A, Furlong F. Weiner-Gorzel K, et al. Among authors: furlong f. Cancer Med. 2015 May;4(5):745-58. doi: 10.1002/cam4.409. Epub 2015 Feb 15. Cancer Med. 2015. PMID: 25684390 Free PMC article.
FKBPL-based peptide, ALM201, targets angiogenesis and cancer stem cells in ovarian cancer.
Annett S, Moore G, Short A, Marshall A, McCrudden C, Yakkundi A, Das S, McCluggage WG, Nelson L, Harley I, Moustafa N, Kennedy CJ, deFazio A, Brand A, Sharma R, Brennan D, O'Toole S, O'Leary J, Bates M, O'Riain C, O'Connor D, Furlong F, McCarthy H, Kissenpfennig A, McClements L, Robson T. Annett S, et al. Among authors: furlong f. Br J Cancer. 2020 Feb;122(3):361-371. doi: 10.1038/s41416-019-0649-5. Epub 2019 Nov 27. Br J Cancer. 2020. PMID: 31772325 Free PMC article.
MAD2 downregulation in hypoxia is independent of promoter hypermethylation.
Prencipe M, McGoldrick A, Perry AS, O'Grady A, Phelan S, McGrogan B, Fitzpatrick P, Watson JA, Furlong F, Brennan DJ, Lawler M, Kay E, McCann A. Prencipe M, et al. Among authors: furlong f. Cell Cycle. 2010 Jul 15;9(14):2856-65. Epub 2010 Jul 12. Cell Cycle. 2010. PMID: 20676051
HDAC6 Degradation Inhibits the Growth of High-Grade Serous Ovarian Cancer Cells.
Ali A, Zhang F, Maguire A, Byrne T, Weiner-Gorzel K, Bridgett S, O'Toole S, O'Leary J, Beggan C, Fitzpatrick P, McCann A, Furlong F. Ali A, et al. Among authors: furlong f. Cancers (Basel). 2020 Dec 11;12(12):3734. doi: 10.3390/cancers12123734. Cancers (Basel). 2020. PMID: 33322608 Free PMC article.
Recurrence of urothelial carcinoma of the bladder: a role for insulin-like growth factor-II loss of imprinting and cytoplasmic E-cadherin immunolocalization.
Gallagher EM, O'Shea DM, Fitzpatrick P, Harrison M, Gilmartin B, Watson JA, Clarke T, Leonard MO, McGoldrick A, Meehan M, Watson C, Furlong F, O'Kelly P, Fitzpatrick JM, Dervan PA, O'Grady A, Kay EW, McCann A. Gallagher EM, et al. Among authors: furlong f. Clin Cancer Res. 2008 Nov 1;14(21):6829-38. doi: 10.1158/1078-0432.CCR-08-0577. Clin Cancer Res. 2008. PMID: 18980977 Free article.
51 results